跳至主要内容
临床试验/NCT06152029
NCT06152029终止不适用

Efficacy of a Temporary Peripheral Nerve Stimulation System in Patients With Osteoarthritis of the Knee

Wake Forest University Health Sciences2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2023年11月15日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
12
试验地点
2
主要终点
Average change from baseline to end of treatment in average pain intensity measured through BPI-SF item 5.

研究概览

简要总结

The purpose of this study is to demonstrate the treatment outcomes of patients with chronic knee pain secondary to osteoarthritis that have received a temporary peripheral nerve stimulation system.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age of 21 and older
  • Will receive a temporary PNS system for the management of chronic knee pain secondary to osteoarthritis
  • Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English
  • Be willing and capable of giving informed consent
  • Be willing and able to comply with study-related requirements, procedures, and scheduled visits

排除标准

  • No knee pain at rest
  • Same nerve targeted for both Radiofrequency Ablation (RFA) and Peripheral Nerve Stimulation (PNS) in less than 6 months post RFA, if applicable
  • Pregnancy
  • History of repetitive skin infections
  • Vulnerable populations (e.g., prisoners, minors, students, employees)
  • Any other condition that may interfere with the ability to participate in a clinical trial (e.g., anatomy that may interfere with lead placement, nerve damage, compromised immune system, uncontrolled diabetes)
  • Confounding conditions such as lumbar radiculopathy
  • Deep brain stimulation system, implanted active cardiac implant (e.g. pacemaker of defibrillator), or any other implantable neuro-stimulator whose stimulus current pathway may overlap the SPRINT system.
  • Be involved in an injury claim under current litigation
  • Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain
  • Have a pending or approved worker's compensation claim

结局指标

主要结局

Average change from baseline to end of treatment in average pain intensity measured through BPI-SF item 5.

时间窗: up to 60 days post lead placement

次要结局

  • Overall patient global impression of change (PGIC) at end of treatment.(up to 60 days post lead placement)
  • Overall incidence of lead migration/fracture during the study.(12 months)
  • Average change from baseline to 6- and 12-months post-explant in pain interference measured through BPI-SF.(7 and 30 days post lead placement; and 6 and 12 month post lead pull)
  • Average change from baseline to end of treatment in health-related quality of life measured through PROMIS-29.(up to 60 days post lead placement)
  • Average change from baseline to end of treatment in pain interference measured through BPI-SF.(up to 60 days post lead placement)
  • Average change in chronic pain related medication intake at end of treatment compared to baseline in Morphine Miligram Equivalents (MME)(up to 60 days post lead placement)
  • Overall incidence of lead migration/fracture at the end of treatment.(up to 60 days post lead placement)
  • Average change from baseline to 7- and 30-days post-implant; and 6- and 12-months post-explant in average pain intensity measured through BPI-SF item 5.(7 and 30 days post lead placement; and 6 and 12 month post lead pull)
  • Average change from baseline to 6- and 12-months post-explant in health-related quality of life measured through PROMIS-29.(7 and 30 days post lead placement; and 6 and 12 month post lead pull)
  • Overall patient global impression of change (PGIC) at 6 months and end of study.(6 and 12 months post lead pull)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Temporary Peripheral Nerve Stimulation System for... | 临床试验